Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications (Q35693269)

9 August 2017

1 reference

title

Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications (English)

1 reference

9 August 2017

1 reference

Kristina Melkersson

1

1 reference

PubMed ID

15025545

9 August 2017

Marja-Liisa Dahl

series ordinal

2

1 reference

9 August 2017

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

64

1 reference

9 August 2017

701-723

1 reference

9 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200464070-00003

9 August 2017

0 references

cites work

No evidence for a direct effect of clozapine on fat-cell formation and production of leptin and other fat-cell-derived factors

1 reference

12 December 2020

Olanzapine increases weight and serum triglyceride levels.

1 reference

12 December 2020

Clozapine and diabetic ketoacidosis

1 reference

12 December 2020

Glucose intolerance with atypical antipsychotics

1 reference

12 December 2020

Diabetic ketoacidosis with olanzapine treatment

1 reference

12 December 2020

Clozapine-associated elevation of plasma cholinesterase

1 reference

12 December 2020

Diabetes mellitus in schizophrenic patients

1 reference

12 December 2020

Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses

1 reference

12 December 2020

New-onset diabetes mellitus associated with quetiapine

1 reference

12 December 2020

Hyperglycemia and antipsychotic medications.

1 reference

12 December 2020

Review of atypical antipsychotics and weight gain.

1 reference

12 December 2020

Association of olanzapine-induced weight gain with an increase in body fat.

1 reference

12 December 2020

Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine.

1 reference

12 December 2020

Chlorpromazine induced diabetes

1 reference

12 December 2020

Drug-induced hyperglycemia

1 reference

12 December 2020

Severe hyperglycemia associated with high doses of clozapine

1 reference

12 December 2020

Leptin, leptin receptors, and the control of body weight.

1 reference

12 December 2020

Positional cloning of the mouse obese gene and its human homologue

1 reference

12 December 2020

Diabetic ketoacidosis with clozapine treatment

1 reference

12 December 2020

Simultaneous side effects of both clozapine and valproate

1 reference

12 December 2020

Elevated serum triglycerides with clozapine resolved with risperidone in four patients

1 reference

12 December 2020

Diabetic ketoacidosis associated with clozapine treatment

1 reference

12 December 2020

Quetiapine-associated hyperglycemia and hypertriglyceridemia

1 reference

12 December 2020

New onset diabetes and atypical antipsychotics

1 reference

12 December 2020

Leptin concentrations and insulin sensitivity in normoglycemic men

1 reference

12 December 2020

Serum leptin levels increase rapidly after initiation of clozapine therapy

1 reference

12 December 2020

Fatality from olanzapine induced hyperglycemia.

1 reference

12 December 2020

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

1 reference

12 December 2020

Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro

1 reference

12 December 2020

Do triglycerides modulate the effectiveness of clozapine?

1 reference

12 December 2020

Risperidone-associated new-onset diabetes

1 reference

12 December 2020

Weight gain and hyperglycaemia associated with olanzapine

1 reference

12 December 2020

Olanzapine-induced elevation of plasma triglyceride levels

1 reference

12 December 2020

The effects of novel antipsychotics on glucose and lipid levels.

1 reference

12 December 2020

Are African American patients at a higher risk for olanzapine-induced glucose intolerance?

1 reference

12 December 2020

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

12 December 2020

The distribution of body mass index among individuals with and without schizophrenia.

1 reference

12 December 2020

Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy

1 reference

12 December 2020

Near fatal ketoacidosis with olanzapine treatment

1 reference

12 December 2020

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

1 reference

12 December 2020

Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment.

1 reference

12 December 2020

Direct stimulation of basal insulin secretion by physiological concentrations of leptin in pancreatic beta cells

1 reference

12 December 2020

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

12 December 2020

A review of the effect of atypical antipsychotics on weight

1 reference

12 December 2020

Diabetic ketoacidosis associated with clozapine treatment

1 reference

12 December 2020

[Hyperglycemia and ketoacidosis associated with olanzapine]

1 reference

12 December 2020

Clozapine use and risk of diabetes mellitus

1 reference

12 December 2020

Hyperglycemia associated with the use of atypical antipsychotics.

1 reference

12 December 2020

Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.

1 reference

12 December 2020

Is leptin the link between obesity and insulin resistance?

1 reference

12 December 2020

Atypical antipsychotics and weight gain--a systematic review

1 reference

12 December 2020

Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation.

1 reference

12 December 2020

Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone

1 reference

12 December 2020

Blood Sugar Levels in Patients Treated with Chlorpromazine

1 reference

12 December 2020

Olanzapine-induced diabetes mellitus

1 reference

12 December 2020

Diabetic ketoacidosis associated with olanzapine in an adolescent patient

1 reference

12 December 2020

Too many chronic mentally disabled patients are too fat.

1 reference

12 December 2020

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

1 reference

12 December 2020

Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study

1 reference

12 December 2020

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

12 December 2020

Clozapine-associated elevation in serum triglycerides

1 reference

12 December 2020

Clozapine and associated diabetes mellitus

1 reference

12 December 2020

Schizophrenia and diabetes mellitus

1 reference

12 December 2020

Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series

1 reference

12 December 2020

Olanzapine-induced glucose dysregulation.

1 reference

12 December 2020

The apparent effects of ziprasidone on plasma lipids and glucose.

1 reference

12 December 2020

Atypical antipsychotics and hyperglycaemia

1 reference

12 December 2020

Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight.

1 reference

12 December 2020

Kelly West Lecture 1991. Challenges in diabetes epidemiology--from West to the rest

1 reference

12 December 2020

Clozapine monotherapy and ketoacidosis

1 reference

12 December 2020

Direct antidiabetic effect of leptin through triglyceride depletion of tissues.

1 reference

12 December 2020

The effect of clozapine on glucose metabolism.

1 reference

12 December 2020

Olanzapine-induced diabetic ketoacidosis

1 reference

12 December 2020

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities

1 reference

12 December 2020

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

1 reference

12 December 2020

Resolution of hyperglycemia on risperidone discontinuation: a case report.

1 reference

12 December 2020

Clozapine-induced diabetic ketoacidosis

1 reference

12 December 2020

Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications

1 reference

12 December 2020

The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.

1 reference

12 December 2020

Clozapine-associated diabetes

1 reference

12 December 2020

Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases

1 reference

12 December 2020

DIABETES MELLITUS AS A SIDE EFFECT OF TREATMENT WITH TRICYCLIC NEUROLEPTICS.

1 reference

12 December 2020

Diabetic ketoacidosis from clozapine and lithium cotreatment

1 reference

12 December 2020

Lactic acidosis and fatal myocardial failure due to clozapine.

1 reference

12 December 2020

Olanzapine-induced ketoacidosis with diabetes mellitus

1 reference

12 December 2020

Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)?

1 reference

12 December 2020

1 reference

12 December 2020

Olanzapine-associated diabetes mellitus

1 reference

12 December 2020

New-onset diabetes and ketoacidosis with atypical antipsychotics

1 reference

12 December 2020

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.

1 reference

12 December 2020

Insulin-resistant hyperglycemia induced by clozapine.

1 reference

12 December 2020

Haemolytic anemia, jaundice and diabetes mellitus following chlorpromazine therapy.

1 reference

12 December 2020

Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol

1 reference

12 December 2020

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

1 reference

12 December 2020

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

1 reference

12 December 2020

Olanzapine and quick-response hyperglycemia

1 reference

12 December 2020

Hyperglycemia in patients with schizophrenia who are treated with olanzapine

1 reference

12 December 2020

Hyperglycemia and hypertriglyceridemia secondary to olanzapine

1 reference

12 December 2020

Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.

1 reference

12 December 2020

Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?

1 reference

12 December 2020

Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland

1 reference

12 December 2020

Increasing insulin dose for olanzapine-related diabetes

1 reference

12 December 2020

Olanzapine-lnduced hyperglycemic nonketonic coma

1 reference

12 December 2020

Effects of atypical antipsychotics on weight and serum lipid levels

1 reference

12 December 2020

Different effects of antipsychotic drugs on insulin release in vitro

1 reference

12 December 2020

Recovery from new-onset diabetes in a schizophrenic man after withdrawal of olanzapine

1 reference

12 December 2020

The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.

1 reference

12 December 2020

Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics

1 reference

12 December 2020

A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder

1 reference

12 December 2020

Olanzapine-associated type 2 diabetes mellitus

1 reference

12 December 2020

Pregnancy of a patient treated with clozapine

1 reference

12 December 2020

The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients

1 reference

12 December 2020

Body weight and leptin plasma levels during treatment with antipsychotic drugs.

1 reference

12 December 2020

New-onset diabetes mellitus associated with the initiation of quetiapine treatment

1 reference

12 December 2020

Hyperglycemia associated with olanzapine

1 reference

12 December 2020

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

12 December 2020

Effects of long-term treatment with antipsychotics on serum leptin levels

1 reference

12 December 2020

Novel antipsychotics and severe hyperlipidemia

1 reference

12 December 2020

Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia

1 reference

12 December 2020

Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics

1 reference

12 December 2020

Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus

1 reference

12 December 2020

Diabetic ketoacidosis and clozapine

1 reference

12 December 2020

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

1 reference

12 December 2020

Risperidone-associated diabetic ketoacidosis

1 reference

12 December 2020

Bodyweight gain with atypical antipsychotics. A comparative review

1 reference

12 December 2020

Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men.

1 reference

12 December 2020

Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine.

1 reference

12 December 2020

Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.

1 reference

12 December 2020

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

1 reference

12 December 2020

Risperidone treatment for a patient suffering from schizophrenia and IDDM

1 reference

12 December 2020

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

1 reference

12 December 2020

Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature

1 reference

12 December 2020

Ketoacidosis as a side-effect of clozapine: a case report

1 reference

12 December 2020

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database

1 reference

12 December 2020

Serum triglyceride levels in patients treated with clozapine

1 reference

12 December 2020

Atypical antipsychotic drug use and diabetes

1 reference

12 December 2020

Diabetes as a result of atypical anti-psychotic drugs--a report of three cases

1 reference

12 December 2020

Novel antipsychotics and new onset diabetes

1 reference

12 December 2020

Euglycemic clamp study in clozapine-induced diabetic ketoacidosis

1 reference

12 December 2020

Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan

1 reference

12 December 2020

Hyperglycemia, hyperlipemia, and periodic paralysis: a case report of new side effects of clozapine

1 reference

12 December 2020

The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

12 December 2020

The impact of clozapine treatment on serum lipids in chronic schizophrenic patients

1 reference

12 December 2020

Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents

1 reference

12 December 2020

Diabetic ketoacidosis associated with risperidone treatment?

1 reference

12 December 2020

Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report.

1 reference

12 December 2020

Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment.

1 reference

12 December 2020

A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year

1 reference

12 December 2020

Risperidone-associated diabetes mellitus: a pharmacovigilance study

1 reference

12 December 2020

Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro

1 reference

12 December 2020

Chlorpromazine in Women with Chronic Schizophrenia: The Effect on Cholesterol Levels and Cholesterol-Behavior Relationships

1 reference

12 December 2020

Phenothiazines and Diabetes in Hospitalized Women

1 reference

12 December 2020

Olanzapine-induced destabilization of diabetes in the absence of weight gain

1 reference

12 December 2020

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

1 reference

12 December 2020

Diabetes mellitus associated with clozapine therapy

1 reference

12 December 2020

Olanzapine and hypertriglyceridemia

1 reference

12 December 2020

Ziprasidone alternative for olanzapine-induced hyperglycemia

1 reference

12 December 2020

Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature

1 reference

12 December 2020

Severe hypertriglyceridemia associated with olanzapine.

1 reference

12 December 2020

Hyperglycemia and olanzapine

1 reference

12 December 2020

The effect of clozapine on blood glucose metabolism

1 reference

12 December 2020

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

12 December 2020

10.2165/00003495-200464070-00003

Identifiers

DOI

1 reference

PubMed ID

15025545

Dimensions Publication ID

9 August 2017

0 references

1 reference

PubMed ID

15025545